Formation of Two Consecutive Intrathecal Catheter Tip Granulomas within Nine Months

Abstract

The formation of catheter tip granulomas is an increasingly observed serious complication of intrathecally administered medication. This complication, which is frequently associated with neurological disturbances, has previously been attributed to high dosages and high concentrations of intrathecal morphine. Much less commonly, intrathecal hydromorphone and intrathecal baclofen have also been associated with intrathecal granuloma formation. In the current case, we report a patient who developed her first catheter tip granuloma after 20 months of intrathecal morphine. After surgical granuloma removal and installation of a new catheter, the patient received intrathecal ziconitide for an interim period of six months. Because of a progressive inefficacy, ziconitide was replaced by hydromorphone. One month later, only nine months after the first operative granuloma removal, a new catheter tip granuloma required a further surgical intervention. This case report highlights the potential of intrathecal morphine and hydromorphone to form consecutive inflammatory granulomas within the same patient. To the best of our knowledge, this is the first report of a patient developing two consecutive catheter tip granulomas within nine months.

Key words

intrathecal medication - intrathecal opioid administration - catheter tip granuloma - ziconitide - pump system control

References

• 1 Ackerman LL, Follett KA, Rosenquist RW. Long-term outcomes during treatment of chronic pain with intrathecal clonidine or clonidine/opioid combinations.  J Pain Symptom Manage. 2003;  26 668-677
• 2 Allen JW, Horais KA, Tozier NA. et al . Time course and role of morphine dose and concentration in intrathecal granuloma formation in dogs: a combined magnetic resonance imaging and histopathology investigation.  Anesthesiology. 2006;  105 581-589
• 3 Coffey RJ, Burchiel K. Inflammatory mass lesions associated with intrathecal drug infusion catheters: report and observations on 41 patients.  Neurosurgery. 2002;  50 78-87
• 4 Deer TR, Raso LJ, Garten TG. Inflammatory mass of an intrathecal catheter in patients receiving baclofen as a sole agent: a report of two cases and a review of the identification and treatment of the complication.  Pain Med. 2007;  8 259-262
• 5 Jones TF, Feler CA, Simmons PB. et al . Neurologic complications including paralysis after a medication error involving implanted intrathecal catheters.  Am J Med. 2002;  112 31-36
• 6 MacMillan MR, Doud T, Nugent W. Catheter-associated masses in patients receiving intrathecal analgesic therapy.  Anesth Analg. 2003;  96 186-190
• 7 Miele VJ, Bloomfield S, Hoog J. et al . A review of intrathecal morphine therapy related granulomas.  Eur J Pain. 2006;  10 251-261
• 8 Ramsey CN, Owen RD, Witt WO. et al . Intrathecal granuloma in a patient receiving high dose hydromorphone.  Pain Physician. 2008;  11 369-373
• 9 Saulino M. Successful reduction of neuropathic pain associated with spinal cord injury via of a combination of intrathecal hydromorphone and ziconotide: a case report.  Spinal Cord. 2007;  45 749-752
• 10 Shields DC, Palma C, Khoo LT. et al . Extramedullary intrathecal catheter granuloma adherent to the conus medullaris presenting as cauda equina syndrome.  Anesthesiology. 2005;  102 1059-1061
• 11 Yaksh TL, Hassenbusch S, Burchiel K. et al . Inflammatory masses associated with intrathecal drug infusion: a review of preclinical evidence and human data.  Pain Med. 2002;  3 300-312

Correspondence